IRIX IRIDEX CORP
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1006045 · Fiscal year ends 01/03
Financial factors as of 2026-10-03 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.8%
TTM net income YoY33.7%
TTM EPS YoY36.7%
Revenue 3-yr CAGR-3.4%
Net income 3-yr CAGR—
Margins
Gross margin38.2%
Operating margin-5.1%
Net margin-6.9%
FCF margin-3.7%
EBITDA margin-4.2%
Returns
ROE-92.4%
ROA-11.7%
ROIC (approx.)—
Asset turnover1.71x
Leverage & solvency
Liabilities / assets91.0%
Debt / equity0.00x
Current ratio1.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.45x
Accruals ratio-6.5%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-01-03 | FY20242024-12-28 |
|---|---|---|
| Income statement | ||
| Revenue | $52.67M | $48.67M |
| Cost of revenue | $33.45M | $29.17M |
| Gross profit | $19.23M | $19.50M |
| R&D expense | $3.67M | $5.45M |
| SG&A expense | $7.73M | $9.78M |
| Operating income | -$2.57M | -$8.30M |
| Interest expense | $58,000 | $146,000 |
| Pretax income | -$4.38M | -$8.84M |
| Income tax | $57,000 | $68,000 |
| Net income | -$4.44M | -$8.91M |
| EBITDA | -$2.05M | -$7.72M |
| EPS (basic) | -0.26 | -0.54 |
| EPS (diluted) | -0.26 | -0.54 |
| Weighted avg. shares (diluted) | 16.93M | 16.44M |
| Balance sheet | ||
| Cash & equivalents | $6.03M | $2.39M |
| Receivables | $7.61M | $5.95M |
| Inventory | $7.88M | $10.82M |
| Current assets | $25.25M | $23.56M |
| PP&E, net | $58,000 | $115,000 |
| Goodwill | $965,000 | $965,000 |
| Intangibles | $984,000 | $1.31M |
| Total assets | $29.15M | $29.14M |
| Current liabilities | $13.21M | $16.56M |
| Short-term debt | — | $1.70M |
| Long-term debt | — | $1.00M |
| Total debt | — | $2.70M |
| Total liabilities | $24.23M | $27.04M |
| Shareholders' equity | $4.92M | $2.10M |
| Net debt | — | $313,000 |
| Shares outstanding | 17.31M | 16.64M |
| Cash flow statement | ||
| Operating cash flow | -$2.12M | -$7.29M |
| Capital expenditure | $143,000 | $13,000 |
| Free cash flow | -$2.26M | -$7.30M |
| Investing cash flow | -$143,000 | -$13,000 |
| Financing cash flow | $5.96M | $2.60M |
| Depreciation & amortization | $523,000 | $584,000 |
| Stock-based compensation | $775,000 | $1.24M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.